Daily Morning Note – 7 Aug 2019

WEEKLY MARKET OUTLOOK WEBINAR

Register HERE for MONDAY’s 11.15am webinar.

Archived webinars available.

PHILLIP SUMMARY

U.S. stocks finally rallied Tuesday after six days of declines and following the biggest losing day so far this year on Monday. Stocks with business in China such as Apple, Micron Technology and Nike that were big losers on Monday led the gains Tuesday. Investors took fright Monday as China allowed the yuan to slump to its lowest level in a decade after President Donald Trump’s threat last Thursday to impose 10% tariffs against an additional $300 billion of imported Chinese goods, effective Sept. 1.The Dow Jones Industrial Average rose 311.78 points, or 1.2%, to end at 26,029.52, while the S&P 500 index climbed 37.03 points, or 1.3%, to close at 2.881.77, powered by a rally by the information technology XLK, +1.66% and communication services XLC, +1.45% sectors, while the Nasdaq Composite Index surged 107.23 points, or 1.4%, to finish at 7,833.27. Traders were encouraged by China’s central bank moving to restrain the fall in its currency with a fix Tuesday at 6.9683 yuan. A breach of the 7-to-the dollar level on Monday, interpreted by some as an intentional weakening of its currency, helped to ignite a global stock market selloff and slump in bond yields.


BREAKING NEWS

The Singapore Exchange (SGX) and the National Stock Exchange of India (NSE) have obtained regulatory support for a joint proposal to have trades in SGX’s popular Nifty futures contracts executed in Gujarat International Financial Services Centre, or GIFT City.

Singapore Medical Group (SMG) boosts ownership in Vietnam clinics. SMG said on Tuesday that it has exercised its option to convert the convertible loan of US$689,360 granted to CityClinic Asia Investments (CCAI) into 177,670 shares of CCAI at the conversion price of US$3.88 per share. Upon conversion, SMG will acquire an additional 65,647 shares from six existing shareholders of CCAI at a price of US$3.88 per share for a total cash consideration of US$255,000.

EC World Reit on Tuesday posted lower second-quarter distribution per unit (DPU) of 1.547 Singapore cents from 1.57 cents, as gross revenue fell amid “an uncertain macro environment”, according to the Chinese e-commerce logistics-focused Reit.

China Sunsine Chemical Holdings on Tuesday posted a net profit of 155.8 million yuan (S$31 million) in the second quarter, down 35 per cent from the same period a year earlier. Revenue in the three months ended June 30 fell 17 per cent to 727 million yuan as a lower average selling price (ASP) offset a rise in sales volume.

StarHub saw earnings fall again by the double-digits in the second quarter on weaker operating profits and higher finance costs, in results released on Tuesday.

Source: The Business Times

TECHNICAL PULSE

Straits Times Index

Recommended Action: Range Trade

Singapore benchmark equity index, FTSE Straits Times Index, has finally seen some light at the end of the tunnel yesterday after rounds of intense selling since last week.

Read more technical pulse

RESEARCH REPORTS

StarHub Ltd – Feeling the pain from fibre migration

Recommendation: ACCUMULATE (Maintained), Last Done: S$1.48

Target Price: S$1.58 (prev. S$1.62), Analyst: Alvin Chia

– Revenue met expectations while net profit disappointed by 22%. Net profit was impacted by expanding losses in cybersecurity and one-off expenses in the fibre migration exercise.

– Mobile services revenue performed better than expected. Post-paid and pre-paid ARPU improved alongside with post-paid subscriber growth.

– Cybersecurity service revenue surged 37% QoQ / 162% YoY but expanded losses.

– Maintain ACCUMULATE with a lower TP of S$1.58. We revised EBITDA and net profit downwards by 4% and 6% respectively in light of the results.

Penguin International Ltd – Record flight for this bird

Recommendation: BUY (Maintained), Last Done: S$0.49

Target Price: S$0.61 Analyst: Paul Chew

– Record quarterly revenue and earnings. No changes to our earnings forecast.

– No order book details but the outlook is positive based on the jump in inventories, assets held for sale and other payables.

– Balance sheet in net cash position of S$47.8mn, or 44% of the market capitalisation.

– Our BUY recommendation and target price of S$0.61 is unchanged.

NetLink NBN Trust – Solid residential connections growth

Recommendation: ACCUMULATE (Maintained), Last Done: S$0.87

Target Price: S$0.93, Analyst: Alvin Chia

– Results were within expectations — strong growth of 4.2% QoQ in residential connections.

– The number of NBAP connections decreased by 5.2% QoQ due to the review of the Smart Nation Sensor Platform programme.

– EBITDA margin is higher due to the adoption of SFRS (I) 16. We have incorporated the new accounting standard into our model.

– Maintain ACCUMULATE with an unchanged target price of S$0.93. Our valuation is based on DCF (WACC 6%, Terminal growth 1%).

Webinar Of The Week

Market Outlook: : : (PSR) CapitaLand Mall Trust, Frasers Centrepoint Trust, JP Morgan, US Weekly, China Weekly Musings, China Brokerage Sector, Technical Outlook

Date: 29 July 2019

For more on Market Outlook

Clients of Phillip Securities can keep updated with Country Strategy and Singapore Sector Reports by logging into: www.poems.com.sg > STOCKS > Research

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided “as is” without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com